阿美纳尔制药有限公司-A 2025年季度报告

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period endedMarch 31, 2025 ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 Commission file number001-38485Amneal Pharmaceuticals, Inc. Delaware(State or other jurisdiction of incorporation or organization)Amneal Pharmaceuticals, Inc. 400 Crossing Boulevard,Bridgewater,NJ08807(Address of principal executive offices)(Zip Code)(908)947-3120(Registrant’s telephone number, including area code)Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registered of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth Large accelerated filer☒Accelerated filer Emerging growth company Table of Contents Consolidated Statements of Cash Flows 1 This Quarterly Report on Form 10-Q and other publicly available documents of Amneal Pharmaceuticals, Inc. contain “forward-looking statements” within the meaning of the safe harbor provisions of the United States (“U.S.”) Private Securities Litigation “us”, or “our”) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly tohistorical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “will,” “anticipates,” “targets,” “estimates,” andother words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating resultsand financial performance; impact of planned acquisitions and dispositions; our strategy for growth; product development; regulatory realize that if underlying assumptions prove inaccurate, known or unknown risks or uncertainties materialize, or other factors orcircumstances change, our actual results and financial condition could vary materially from expectations and projections expressed or Risks and uncertainties that make an investment in the Company speculative or risky or that could cause our actual results to differmaterially from the forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to:•our ability to successfully develop, license, acquire and commercialize new products on a timely basis;•the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact ofthat competition on our ability to set prices;•our ability to obtain exclusive marketing rights for our products;•the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products;•the impact of negative market perceptions of us and the safety and quality of our products;•our revenues are derived from the sales of a limited number of products, a substantial portion of which are through alimitednumber of customers;•the continuing trend of consolidation of certain customer groups; •our obligations under a tax receivable agreement may be significant;•the high concentration of ownership of our Class A common stock and the fact that we are controlled by the Amneal Group(as defined inItem 1. Businessin the Company’s 2024 Annual Report on Form 10-K); and and should not consider the risks described herein and in our Annual Report to be a complete statement of all potential risks anduncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time,whether as a result of new information or future events or developments. Employee payroll tax withholding on restricted stock unit and performance stock unit vesting ————————— Net (loss) incomeForeign currency translation Stock-based compensation——6,722———6,722Exercise of stock options10—28———28Restricted stock unit vesting, net ofshares withheld to cover payroll2,04820(7,270)———(7,250)Unrealized gain on cash flow Amneal Pharmaceuticals, Inc.Notes to Consolidated Financial Statements(unaudited) Basis of Presentation Customer A24%Customer B15%Customer C21% Company’s reportable segments and, therefore, did not change historical total net revenue in any segment. All prior periods werechanged to conform to the current period’s presentation. The Company’s significant dosage forms for its Affordable Medicines segment, therapeutic classes for its Specialty segment and saleschannels for its AvKARE segment, as determined based on net revenue for the three months ended March31, 2025 and 2024, are s